These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33201868)

  • 21. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.
    Zent CS; Brady MT; Delage C; Strawderman M; Laniewski N; Contant PN; Kanagaiah P; Sangster MY; Barr PM; Chu CC; Topham DJ; Friedberg JW
    Leukemia; 2021 Jun; 35(6):1788-1791. PubMed ID: 33128020
    [No Abstract]   [Full Text] [Related]  

  • 24. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 25. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia.
    Lewis RI; Vom Stein AF; Hallek M
    Blood; 2024 Aug; 144(6):601-614. PubMed ID: 38776510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
    Lucas F; Woyach JA
    Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.
    Shao Y; Kay NE; Gale RP; Liang Y
    Leukemia; 2024 Jul; 38(7):1469-1473. PubMed ID: 38824147
    [No Abstract]   [Full Text] [Related]  

  • 29. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
    Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.
    Wanquet A; Birsen R; Lemal R; Hunault M; Leblond V; Aurran-Schleinitz T
    Blood; 2016 May; 127(19):2356-8. PubMed ID: 26994148
    [No Abstract]   [Full Text] [Related]  

  • 33. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
    Burger JA; Li KW; Keating MJ; Sivina M; Amer AM; Garg N; Ferrajoli A; Huang X; Kantarjian H; Wierda WG; O'Brien S; Hellerstein MK; Turner SM; Emson CL; Chen SS; Yan XJ; Wodarz D; Chiorazzi N
    JCI Insight; 2017 Jan; 2(2):e89904. PubMed ID: 28138560
    [No Abstract]   [Full Text] [Related]  

  • 34. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
    Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
    Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing CLL that has progressed after BTK inhibition.
    Roeker L
    Clin Adv Hematol Oncol; 2023 Jun; 21(6):300-303. PubMed ID: 37530635
    [No Abstract]   [Full Text] [Related]  

  • 36. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
    Chan TS; Au-Yeung R; Chim CS; Wong SC; Kwong YL
    Ann Hematol; 2017 May; 96(5):871-872. PubMed ID: 28184982
    [No Abstract]   [Full Text] [Related]  

  • 37. Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on.
    Molica S; Matutes E; Tam C; Polliack A
    Hematol Oncol; 2020 Apr; 38(2):129-136. PubMed ID: 31732977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
    Foluso O; Glick A; Stender M; Jaiyesimi I
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):63-9. PubMed ID: 26775273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
    Barrientos J; Rai K
    Leuk Lymphoma; 2013 Aug; 54(8):1817-20. PubMed ID: 23617325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.